Prescription Drugmakers: Defensive Momentum

Druck Drake’s thesis

Buy prescription-drug franchises where price strength is confirming a rotation away from speculative technology and toward resilient healthcare demand. These drugmakers have positive monthly and quarterly momentum, supporting an earnings-led exposure without assuming easier Fed policy or a liquidity rescue. Patent expirations, clinical setbacks and pricing pressure remain material risks; abandon the rotation if relative strength breaks rather than treating defensiveness as guaranteed downside pr